23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › IDEAYA Biosciences, Inc. › 2025-2026

IDEAYA Biosciences, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and IDEAYA Biosciences, Inc.’s Form 8-K, filed June 23, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 5Ballot items
  • 286Asset managers, any item
  • 1,543Fund votes
  • June 16, 2026Meeting date

Results at a glance

Meeting of June 16, 2026: 5 items on IDEAYA Biosciences, Inc.’s Form 8-K, filed June 23, 2026: 5 passed (calculated).

Dissent

Significant dissent: 1 director (22.3% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore IDEAYA Biosciences, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by IDEAYA Biosciences, Inc.

These tallies are IDEAYA Biosciences, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 23, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

IDEAYA Biosciences, Inc. — official shareholder meeting results, meeting held June 16, 2026
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Yujiro S. Hata 70,546,418---- 2,470,07710,089,343 97%Passed (calculated)—
Elect Director: M. Garret Hampton, Ph.D. 56,718,637---- 16,297,85810,089,343 78%Passed (calculated)—
Elect Director: Catherine J. Mackey, Ph.D. 70,281,521---- 2,734,97410,089,343 96%Passed (calculated)—
2. The ratification of the selection, by the Audit Committee of the Board of Directors of the Company, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the year ending December 31, 2026 82,579,758141,240384,840 ---- 99.8%Passed (calculated)—
3. Non-binding, advisory vote to approve the compensation of the Company's named executive officers 64,269,7568,349,131397,608 --10,089,343 89%Passed (calculated)—

Source: IDEAYA Biosciences, Inc., Form 8-K, filed with the SEC on June 23, 2026 — read the filing on EDGAR.

How asset managers voted at the IDEAYA Biosciences, Inc. 2025-2026 meeting

286 asset managers disclosed a vote on at least one IDEAYA Biosciences, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Catherine J. Mackey, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 70,281,521WITHHELD: 2,734,974
Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected: Catherine J. Mackey, Ph.D.

IDEAYA Biosciences, Inc.’s own tally for this item (“Elect Director: Catherine J. Mackey, Ph.D.”): 70,281,521 for, 2,734,974 withheld, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 32,881,085 for, 550,344 withheld, 9 abstained.

FOR
FOR: 32,881,085ABSTAIN: 9WITHHOLD: 550,344
Largest asset managers voting on “To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their s” at IDEAYA Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,288,0410 00For
Capital Group5,163,5430 00For
Vanguard4,453,9820 90For
BlackRock3,230,3660 00For
JANUS INVESTMENT FUND2,156,6090 00For
State Street1,648,8170 00For
Federated Hermes1,431,6300 00For
T. Rowe Price904,5960 00For
Charles Schwab718,0710 00For
TIAA701,3100 00For
Dimensional00 0447,090Withhold
GENERAL AMERICAN INVESTORS CO INC301,0570 00For
Victory Capital300,9560 00For
First Trust275,2940 00For
Goldman Sachs248,3180 00For
American Century242,2290 00For
Equitable127,4330 068,180Mixed
QUANTITATIVE MASTER SERIES LLC137,4230 00For
New York Life133,8630 00For
Jackson National112,4040 016,326Mixed
Tema ETF Trust128,5460 00For
JPMorgan119,4280 00For
FRANKLIN STRATEGIC SERIES81,8520 00For
ALPS ETF Trust70,7800 00For
Russell Investments61,6800 00For

Showing the 25 largest of 73 asset managers. All 73 are in the interactive database (link above).

Elect Director: M. Garret Hampton, Ph.D.

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

78% Majority: yes · of votes cast

FOR 78%WITHHELD
FOR: 56,718,637WITHHELD: 16,297,858
Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected: M. Garret Hampton, Ph.D.

IDEAYA Biosciences, Inc.’s own tally for this item (“Elect Director: M. Garret Hampton, Ph.D.”): 56,718,637 for, 16,297,858 withheld, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 31,284,057 for, 2,143,547 withheld, 3,834 abstained.

FOR
FOR: 31,284,057ABSTAIN: 3,834WITHHOLD: 2,143,547
Largest asset managers voting on “To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their s” at IDEAYA Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,288,0410 00For
Capital Group5,163,5430 00For
Vanguard4,449,9430 484,001For
BlackRock3,230,3660 00For
JANUS INVESTMENT FUND2,076,4150 080,194For
State Street1,646,9220 01,895For
Federated Hermes1,431,6300 00For
T. Rowe Price904,5960 00For
Charles Schwab718,0710 00For
TIAA701,3100 00For
Dimensional00 0447,090Withhold
GENERAL AMERICAN INVESTORS CO INC301,0570 00For
Victory Capital00 0300,956Withhold
First Trust00 0275,294Withhold
Goldman Sachs248,3180 00For
American Century00 0242,229Withhold
Equitable127,4330 068,180Mixed
QUANTITATIVE MASTER SERIES LLC137,4230 00For
New York Life133,8630 00For
Jackson National112,4040 016,326Mixed
Tema ETF Trust128,5460 00For
JPMorgan119,4280 00For
FRANKLIN STRATEGIC SERIES00 081,852Withhold
ALPS ETF Trust00 070,780Withhold
Russell Investments00 061,680Withhold

Showing the 25 largest of 73 asset managers. All 73 are in the interactive database (link above).

Elect Director: Yujiro S. Hata

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 70,546,418WITHHELD: 2,470,077
Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their successors are elected: Yujiro S. Hata

IDEAYA Biosciences, Inc.’s own tally for this item (“Elect Director: Yujiro S. Hata”): 70,546,418 for, 2,470,077 withheld, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 32,881,087 for, 550,344 withheld, 7 abstained.

FOR
FOR: 32,881,087ABSTAIN: 7WITHHOLD: 550,344
Largest asset managers voting on “To elect three Class I directors to hold office until the 2029 annual meeting of stockholders or until their s” at IDEAYA Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,288,0410 00For
Capital Group5,163,5430 00For
Vanguard4,453,9840 70For
BlackRock3,230,3660 00For
JANUS INVESTMENT FUND2,156,6090 00For
State Street1,648,8170 00For
Federated Hermes1,431,6300 00For
T. Rowe Price904,5960 00For
Charles Schwab718,0710 00For
TIAA701,3100 00For
Dimensional00 0447,090Withhold
GENERAL AMERICAN INVESTORS CO INC301,0570 00For
Victory Capital300,9560 00For
First Trust275,2940 00For
Goldman Sachs248,3180 00For
American Century242,2290 00For
Equitable127,4330 068,180Mixed
QUANTITATIVE MASTER SERIES LLC137,4230 00For
New York Life133,8630 00For
Jackson National112,4040 016,326Mixed
Tema ETF Trust128,5460 00For
JPMorgan119,4280 00For
FRANKLIN STRATEGIC SERIES81,8520 00For
ALPS ETF Trust70,7800 00For
Russell Investments61,6800 00For

Showing the 25 largest of 73 asset managers. All 73 are in the interactive database (link above).

Non-binding, advisory vote to approve the compensation of the Company's named executive officers

Calculated outcomeFund totals may overlapSECTION 14A SAY-ON-PAY VOTESPassed (calculated)

Combines 12 wordings of this item as funds reported it.

89% Majority: yes · of votes cast

FOR 89%
FOR: 64,269,756AGAINST: 8,349,131

Prior year: 77.8% for (June 24, 2025 meeting) ▲ 10.7 pts

Details: description as filed, official tally, votes by 286 asset managers

Description as filed by funds: To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as disclosed in the Proxy Statement accompanying this Notice of Annual Meeting of Stockholders; and

IDEAYA Biosciences, Inc.’s own tally for this item (“3. The non-binding, advisory vote to approve the compensation of the Company's named executive officers”): 64,269,756 for, 8,349,131 against, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 72 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as di” at IDEAYA Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,288,0410 00For
Capital Group05,163,543 00Against
Vanguard4,453,9829 10For
BlackRock3,230,3660 00For
JANUS INVESTMENT FUND2,156,6090 00For
State Street1,648,134683 00For
Federated Hermes1,431,6300 00For
T. Rowe Price904,5960 00For
Charles Schwab718,0710 00For
TIAA701,3100 00For
Dimensional447,0900 00For
GENERAL AMERICAN INVESTORS CO INC301,0570 00For
Victory Capital300,9560 00For
First Trust275,2940 00For
Goldman Sachs248,3180 00For
American Century0242,229 00Against
Equitable195,6130 00For
QUANTITATIVE MASTER SERIES LLC137,4230 00For
New York Life133,8630 00For
Jackson National128,7300 00For
Tema ETF Trust128,5460 00For
JPMorgan119,4280 00For
FRANKLIN STRATEGIC SERIES81,8520 00For
ALPS ETF Trust70,7800 00For
Russell Investments61,6800 00For

Fund voting reports, all 72 managers: 27,992,585 for, 5,444,088 against, 1 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 232 asset managers voting on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive officers as di” at IDEAYA Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Janus Henderson13,520,0750 00For
Fidelity13,171,8210 00For
Capital Research Global Investors05,163,543 00Against
BlackRock3,654,36537,992 00For
Logos Global Management LP3,299,2870 00For
State Street2,994,45617,194 00For
GEODE CAPITAL MANAGEMENT, LLC2,281,9960 00For
DEERFIELD MANAGEMENT COMPANY, L.P.1,684,4010 00For
Federated Hermes1,431,6300 00For
Fiera Capital Corp1,300,99678,024 00Mixed
T. Rowe Price1,349,4830 00For
BNP Paribas Asset Management Holding S.A.1,231,3680 00For
Candriam S.C.A.0998,708 00Against
Ensign Peak Advisors, Inc899,5040 00For
Charles Schwab719,8360 00For
Nuveen713,6780 00For
Vanguard687,5480 00For
PICTET ASSET MANAGEMENT SA641,1340 00For
Aberdeen618,4360 00For
ADAGE CAPITAL PARTNERS GP, L.L.C.544,8000 00For
DAFNA Capital Management LLC476,7400 00For
Redmile Group, LLC455,0170 00For
Northern Trust418,3959,484 00For
Fisher Asset Management, LLC403,0536,704 00For
Sofinnova Investments, Inc.368,5450 00For

Institutional-manager reports, all 232 managers: 57,942,332 for, 7,066,904 against, 24,284 abstained, 258 not voted. Showing the 25 largest; every one is in the interactive database (link above).

The ratification of the selection, by the Audit Committee of the Board of Directors of the Company, of…

Calculated outcomeAUDIT-RELATEDPassed (calculated)

Combines 4 wordings of this item as funds reported it.

99.8% Majority: yes · of votes cast

FOR 99.8%
FOR: 82,579,758AGAINST: 141,240

Prior year: 99.7% for (June 24, 2025 meeting) ▲ 0.1 pts

Details: description as filed, official tally, votes by 73 asset managers

Description as filed by funds: To ratify the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers LLP, as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2026;

IDEAYA Biosciences, Inc.’s own tally for this item (“2. The ratification of the selection, by the Audit Committee of the Board of Directors of the Company, of PricewaterhouseCoopers LLP as the independent registered public accounting firm of the Company for the year ending”): 82,579,758 for, 141,240 against, per its Form 8-K filed June 23, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 99.8% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 73 asset managers below reported 33,436,605 for, 632 against, 1 abstained.

FOR
FOR: 33,436,605AGAINST: 632ABSTAIN: 1
Largest asset managers voting on “To ratify the selection, by the Audit Committee of the Company's Board of Directors, of PricewaterhouseCoopers” at IDEAYA Biosciences, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Fidelity9,288,0410 00For
Capital Group5,163,5430 00For
Vanguard4,453,9900 10For
BlackRock3,230,3660 00For
JANUS INVESTMENT FUND2,156,6090 00For
State Street1,648,75265 00For
Federated Hermes1,431,6300 00For
T. Rowe Price904,5960 00For
Charles Schwab718,0710 00For
TIAA701,3100 00For
Dimensional447,0900 00For
GENERAL AMERICAN INVESTORS CO INC301,0570 00For
Victory Capital300,9560 00For
First Trust275,2940 00For
Goldman Sachs248,3180 00For
American Century242,2290 00For
Equitable195,6130 00For
QUANTITATIVE MASTER SERIES LLC137,4230 00For
New York Life133,8630 00For
Jackson National128,7300 00For
Tema ETF Trust128,5460 00For
JPMorgan119,4280 00For
FRANKLIN STRATEGIC SERIES81,8520 00For
ALPS ETF Trust70,7800 00For
Russell Investments61,6800 00For

Showing the 25 largest of 73 asset managers. All 73 are in the interactive database (link above).

Largest IDEAYA Biosciences, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 87,856,154 shares outstanding at the time of that meeting.

Fund voting reports: top IDEAYA Biosciences, Inc. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Fidelity 10.57%
2Capital Group 5.88%
3Vanguard 5.07%
4BlackRock 3.68%
5JANUS INVESTMENT FUND 2.45%
6State Street 1.88%
7Federated Hermes 1.63%
8T. Rowe Price 1.03%
9Charles Schwab 0.82%
10TIAA 0.80%
Institutional-manager reports: top IDEAYA Biosciences, Inc. shareholders by shares voted on “To approve, on a non-binding, advisory basis, the compensation of the Company's named executive…”, 2025-2026
#Asset manager % of shares outstanding
1Janus Henderson 15.39%
2Fidelity 14.99%
3Capital Research Global Investors 5.88%
4BlackRock 4.20%
5Logos Global Management LP 3.76%
6State Street 3.43%
7GEODE CAPITAL MANAGEMENT, LLC 2.60%
8DEERFIELD MANAGEMENT COMPANY, L.P. 1.92%
9Federated Hermes 1.63%
10Fiera Capital Corp 1.57%

Reported IDEAYA Biosciences, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

IDEAYA Biosciences, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
FMR (Fidelity)13,172,103 14.99%Form 13F, quarter ended March 31, 2026
FMR LLC12,635,652 14.38%Proxy statement (DEF 14A), table as of March 31, 2026
BlackRock8,442,133 9.61%Form 13F, quarter ended March 31, 2026
JANUS HENDERSON GROUP PLC7,265,253 8.27%Schedule 13G, filed May 15, 2026
Capital Research Global Investors5,279,675 6.01%Schedule 13G, filed February 12, 2026
Vanguard Group5,019,324 5.71%Form 13F, quarter ended March 31, 2026
State Street3,781,167 4.30%Form 13F, quarter ended March 31, 2026
Federated Hermes, Inc.3,395,771 3.87%Schedule 13G, filed January 8, 2026
Goldman Sachs1,913,617 2.18%Form 13F, quarter ended March 31, 2026
Point72 Asset Management, L.P.1,844,556 2.10%Schedule 13G, filed February 17, 2026

Percentages above are of 87,856,154 shares outstanding, as reported by IDEAYA Biosciences, Inc. on its Form 10-Q dated March 31, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At IDEAYA Biosciences, Inc.'s shareholder meeting held June 16, 2026, in the 2025-2026 proxy season, 286 asset managers reported votes on at least one of its 5 ballot items in their SEC Form N-PX filings, covering 1,543 separate fund positions. On the most widely held item on that ballot — To approve, on a non-binding, advisory basis, the compensation of the Company's named executive… — FOR was 89% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: IDEAYA Biosciences, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 23, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from IDEAYA Biosciences, Inc.’s 10-Q dated March 31, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

IDEAYA Biosciences, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “IDEAYA Biosciences (IDYA) 2026 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/ideaya-biosciences-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.